• 1 January 1981
    • journal article
    • research article
    • Vol. 218 (2), 509-514
Abstract
Erythromycin, 0.3 mM, elicited a small reverse type I binding spectrum with, and was slowly demethylated by, cytochrome P-450 from control rats. No absorption peak at 456 nm could be detected upon incubation of 0.3 mM erythromycin with NADPH and control microsomes. No complex formed in vivo could be detected in microsomes isolated 2 h after a single dose of erythromycin, 2 mmol.cntdot.kg-1 p.o. [per os]. Repeated administration of erythromycin, 2 mmol.cntdot.kg-1 p.o. daily for 4 days, increased hepatic microsomal protein concentration, NADPH-cytochrome c reductase activity, the amplitude of the reverse type I binding spectrum of erythromycin and erythromycin demethylase activity. Microsomes isolated from rats treated with repeated doses of erythromycin exhibited a marked absorption peak at 456 nm. The absorption at 456 nm was further increased upon incubation with erythromycin and NADPH. It disappeared upon addition of 50 .mu.M potassium ferricyanide. Disruption of the complex with potassium ferricyanide markedly increased the CO-binding capacity of dithionite-reduced microsomes. It further increased the amplitude of the reverse type I binding spectrum of erythromycin and erythromycin demethylase activity and increased ethylmorphine N-demethylase and benzo[a]pyrene hydroxylase activities. Erythromycin apparently induces its own transformation into a metabolite which forms an inactive 456-nm absorbing complex with the iron (II) of cytochrome P-450.